COVID-19 in patients with acute lymphoblastic leukemia

Autor: T. S. Chudnova, E. N. Misyurina, E. A. Baryakh, T. N. Tolstykh, L. T. Shimanovskaya, D. E. Gagloeva, E. I. Zhelnova, A. B. Makeshova, K. V. Yatskov, E. N. Zotina, D. D. Ivanova, M. A. Mingalimov, O. L. Kochneva, E. Yu. Grishina, V. N. Yakimets
Jazyk: ruština
Rok vydání: 2024
Předmět:
Zdroj: Онкогематология, Vol 19, Iss 3, Pp 206-214 (2024)
Druh dokumentu: article
ISSN: 1818-8346
2413-4023
DOI: 10.17650/1818-8346-2024-19-3-206-214
Popis: Background. Patients with acute lymphoblastic leukemia (ALL) have been the most vulnerable group of patients at risk of severe and extremely severe COVID-19 throughout the coronavirus pandemic. Secondary immunodeficiency due to acute leukemia, as well as antitumor treatment, predisposes to the development of a more severe infection, as well as long-term SARS-CoV-2 persistence even after complete regression of COVID-19 symptoms. Thus, although after the emergence of the SARS-CoV-2 Omicron variant, coronavirus infection began to occur predominantly in a mild form, COVID-19 in ALL patients remains an urgent problem.Aim. To assess hospital survival of patients with ALL and concomitant coronavirus infection, to identify predictors of death and to evaluate the impact of program antitumor therapy on the outcome in this cohort of patients.Materials and methods. A retrospective analysis of ALL patients hospitalized in City Clinical Hospital No. 52 with coronavirus infection from February 2020 to December 2022 was conducted. Diagnosis and treatment of patients were carried out in accordance with valid at the time of hospitalization temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”. Univariate and multivariate regression analyses were performed to identify predictors of mortality in patients with ALL and COVID-19. Survival analysis was performed using the Kaplan–Meier method. A p
Databáze: Directory of Open Access Journals
Externí odkaz: